サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1392651

酵素阻害剤の世界市場レポート 2024年

Enzyme Inhibitor Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
酵素阻害剤の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

酵素阻害剤の市場規模は近年着実に成長しています。2023年の1,803億8,000万米ドルから2024年には1,860億4,000万米ドルに、CAGR3.1％で拡大します。実績期間の成長は、様々な疾患の治療における酵素阻害剤の需要の増加、創薬と開発の進歩、慢性疾患の有病率の増加、老人人口の増加、酵素阻害剤の利点に関する意識の高まりに起因しています。

がんを含む疾病の発生率の増加は、酵素阻害剤市場の今後の成長を促進すると予想されます。ほとんどの腫瘍細胞で活性を持つテロメラーゼなどの酵素は、白血病を含むがんを治療するために利用され、また健康な成人細胞ががん化するのを防ぐ。例えば、がん撲滅を目指す米国の非営利ヘルスケア団体である米国がん協会によると、2022年1月、米国では毎日平均1670人ががんで死亡し、190万人ががんと診断され、60万9360人が死亡します。したがって、がんなどの疾病の発生率の上昇が、酵素阻害剤市場の成長需要を牽引しています。

個別化医療に対する需要の高まりが、今後数年間の酵素阻害剤市場の成長を促進すると予想されます。個別化医療は、精密医療とも呼ばれ、DNA、環境、ライフスタイルにおける各人固有の多様性を考慮したヘルスケアおよび治療方法です。酵素阻害剤は、特定の個人や疾患のサブタイプに合わせて調整できるため、個別化医療における貴重なツールであり、集中治療、精密医療、診断、創薬など、個別化医療における幅広い用途があります。例えば、米国を拠点とする製薬、バイオテクノロジー、診断、IT企業、医療提供者、支払者の非営利団体である個別化医療連合（Personalized Medicine Coalition）によると、2022年、個別化医療は米国食品医薬品局（FDA）による新薬承認の34%に寄与し、過去8年間はいずれも承認の25%以上を占めていました。したがって、個別化医療に対する需要の高まりが酵素阻害剤市場を牽引しています。

2023年の酵素阻害剤市場で最大の地域は北米です。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。

目次

第1章 エグゼクティブサマリー

第2章 酵素阻害剤市場の特徴

第3章 酵素阻害剤市場の動向と戦略

第4章 酵素阻害剤市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の酵素阻害剤市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年から2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 酵素阻害剤市場セグメンテーション

  • 世界の酵素阻害剤市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • プロトンポンプ阻害剤（PPI）
  • プロテアーゼ阻害剤
  • 逆転写酵素阻害剤
  • アロマターゼ阻害剤
  • キナーゼ阻害剤
  • ノイラミニダーゼ阻害剤
  • スタチン
  • その他
  • 世界の酵素阻害剤市場、疾患適応症別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 慢性閉塞性肺疾患
  • 循環器疾患
  • 胃腸障害
  • 関節炎
  • 炎症性疾患
  • その他
  • 世界の酵素阻害剤市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028F、2033F
  • 化学療法
  • 抗生物質
  • 農薬
  • 心臓血管の治療
  • その他
  • 世界の酵素阻害剤市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品
  • バイオテクノロジー
  • 食品および飲料
  • その他

第7章 酵素阻害剤市場の地域および国分析

  • 世界の酵素阻害剤市場、地域別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで
  • 世界の酵素阻害剤市場、国別、実績および予測、2018-2023、2023-2028F、2033F

第8章 アジア太平洋の酵素阻害剤市場

  • 概要
  • 地域情報、COVID-19症の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第9章 中国の酵素阻害剤市場

第10章 インドの酵素阻害剤市場

第11章 日本の酵素阻害剤市場

第12章 オーストラリアの酵素阻害剤市場

第13章 インドネシアの酵素阻害剤市場

第14章 韓国の酵素阻害剤市場

第15章 西欧の酵素阻害剤市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第16章 英国の酵素阻害剤市場

第17章 ドイツの酵素阻害剤市場

第18章 フランスの酵素阻害剤市場

第19章 イタリアの酵素阻害剤市場

第20章 スペインの酵素阻害剤市場

第21章 東欧の酵素阻害剤市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第22章 ロシアの酵素阻害剤市場

第23章 北米の酵素阻害剤市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第24章 米国の酵素阻害剤市場

第25章 カナダの酵素阻害剤市場

第26章 南米の酵素阻害剤市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第27章 ブラジルの酵素阻害剤市場

第28章 中東の酵素阻害剤市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第29章 アフリカの酵素阻害剤市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 用途別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第30章 酵素阻害剤市場の競合情勢と企業プロファイル

  • 酵素阻害剤市場の競合情勢
  • 酵素阻害剤市場の企業プロファイル
    • Abbott Laboratories
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • F. Hoffmann-La Roche AG

第31章 世界の酵素阻害剤市場の競合ベンチマーキング

第32章 世界の酵素阻害剤市場競争ダッシュボード

第33章 酵素阻害剤市場における主要な合併と買収

第34章 酵素阻害剤市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10339

“Enzyme Inhibitor Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on enzyme inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for enzyme inhibitor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The enzyme inhibitor market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Proton Pump Inhibitors (PPIs); Protease Inhibitors; Reverse Transcriptase Inhibitors; Aromatase Inhibitors; Kinase Inhibitors; Neuraminidase Inhibitors; Statins; Other Types
  • 2) By Disease Indication: Chronic Obstructive Pulmonary Disorders; Cardiovascular Disease; Gastrointestinal Disorders; Arthritis; Inflammatory Diseases; Other Disease Indications
  • 3) By Application: Chemotherapy; Antibiotics; Pesticides; Cardiovascular Treatments; Other Applications
  • 4) By End User: Pharmaceutical; Biotechnology; Food and Beverage; Other End Users
  • Companies Mentioned: Abbott Laboratories; Amgen Inc.; AstraZeneca plc; Bayer AG; F. Hoffmann-La Roche AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Enzyme inhibitor refers to a chemical that inhibits an enzyme's activity. Enzymes participate in a variety of cell processes, including cell signaling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division.

The main types of enzyme inhibitors are proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, aromatase inhibitors, kinase inhibitors, neuraminidase inhibitors, statins, and other types. Proton pump inhibitors refer to medicines that work by decreasing the amount of stomach acid made by glands in the lining of the stomach. The various disease indications include chronic obstructive pulmonary disorders, cardiovascular disease, gastrointestinal disorders, arthritis, inflammatory diseases, and others. The enzyme inhibitors are applicable in chemotherapy, antibiotics, pesticides, cardiovascular treatments, and others and are used in pharmaceuticals, biotechnology, food and beverage, and other end users.

The enzyme inhibitors market research report is one of a series of new reports from The Business Research Company that provides enzyme inhibitors market statistics, including enzyme inhibitors industry global market size, regional shares, competitors with an enzyme inhibitors market share, detailed enzyme inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme inhibitors industry. This enzyme inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The enzyme inhibitor market size has grown steadily in recent years. It will grow from $180. 38 billion in 2023 to $186. 04 billion in 2024 at a compound annual growth rate (CAGR) of 3. 1%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors in the treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness about the benefits of enzyme inhibitors.

The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $216. 75 billion in 2028 at a compound annual growth rate (CAGR) of 3. 9%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases. .

The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1. 9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.

The increasing demand for personalized medicine is expected to propel the growth of the enzyme inhibitor market in the coming years. Personalized medicine, additionally referred to as precision medicine, is a health care and treatment method that considers each person's specific diversity in DNA, surroundings, and lifestyle. Enzyme inhibitors are a valuable tool in personalized medicine because they can be adjusted to particular individuals or disease subtypes and have a wide range of applications in personalized medicine, including focused therapy, precision medicine, diagnostics, and drug discovery. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based nonprofit umbrella association for pharmaceuticals, biotechnology, diagnosis, and information technology firms, as well as healthcare providers and payers, personalized medications contributed to 34% of new drug approvals by the US Food and Drug Administration and had been responsible for at least 25% of approvals in each of the previous eight years. Therefore, the increasing demand for personalized medicine is driving the enzyme inhibitor market.

Strategic partnerships and collaborations have emerged as a key trend gaining popularity in the enzyme inhibitor market. Major companies operating in enzyme inhibitors are focused on strategic partnerships to meet customer demand. For instance, in April 2021, Artios Pharma Limited, a UK-based DNA damage response company that also provides enzyme inhibitors, collaborated with Novartis International AG, a Switzerland-based pharmaceutical corporation, to uncover and verify new generation DDR (DNA Damage Response) targets to advance Novartis' Radioligand Therapies (RLT). This partnership with Novartis will be utilized to find and validate next-generation DDR targets to improve Novartis' radioligand therapies.

Major companies operating in the enzyme inhibitor market are focusing on developing innovative products, such as Sotyktu, to better meet the needs of their existing consumers. Sotyktu is an allosteric tyrosine kinase 2 (TYK2) inhibitor drug intended to inhibit or limit the activity of the TYK2 enzyme by attaching to a location on the enzyme other than its active site. For instance, in September 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced the approval of Sotyktu, a selective oral allosteric tyrosine kinase 2 (TYK2) inhibitor that is the first of its kind by the U. S. Food and Drug Administration. Sotyktu is a prescription medication authorized for treating people with moderate-to-severe plaque psoriasis who are not candidates for systemic therapy or phototherapy. 1,2 Sotyktu should not be used in conjunction with other strong immunosuppressants. Sotyktu can serve as the new standard of care for oral therapy for persons with moderate-to-severe plaque psoriasis due to its track record of assisting patients in attaining smoother skin in the POETYK PSO clinical study.

In March 2021, Amgen Inc., a US-based biotechnology company, acquired Rodeo Therapeutics Corporation for a deal amount of $666 million. Through this acquisition, Rodeo is focused on developing first-in-class, orally available modulators of prostaglandin biology that play an important role in tissue regeneration and repair. Rodeo Therapeutics Corporation is a US-based biopharmaceutical company that develops enzyme inhibitors.

Major companies operating in the in the enzyme inhibitor market report are Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Ranbaxy Laboratories Limited, Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla USA Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Acellera Ltd., Bioinfogate SL, BioSolveIT GmbH, Dassault Systemes BIOVIA Corp., ChemAxon Ltd., Cheminformatics Tools and Services LLC, Cresset BioMolecular Discovery Ltd., Dotmatics Limited, Enamine Ltd., Forge Therapeutics Inc., Inte:Ligand GmbH, LeadIT, Molecular Forecaster Inc., Chemical Computing Group Inc., OpenEye Scientific Software Inc.

North America was the largest region in the enzyme inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the enzyme inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The enzyme inhibitor market consists of sales of competitive, noncompetitive, and uncompetitive inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Enzyme Inhibitor Market Characteristics

3. Enzyme Inhibitor Market Trends And Strategies

4. Enzyme Inhibitor Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Enzyme Inhibitor Market Size and Growth

  • 5.1. Global Enzyme Inhibitor Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Enzyme Inhibitor Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Enzyme Inhibitor Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Enzyme Inhibitor Market Segmentation

  • 6.1. Global Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Proton Pump Inhibitors (PPIs)
  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Aromatase Inhibitors
  • Kinase Inhibitors
  • Neuraminidase Inhibitors
  • Statins
  • Other Types
  • 6.2. Global Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chronic Obstructive Pulmonary Disorders
  • Cardiovascular Disease
  • Gastrointestinal Disorders
  • Arthritis
  • Inflammatory Diseases
  • Other Disease Indications
  • 6.3. Global Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Antibiotics
  • Pesticides
  • Cardiovascular Treatments
  • Other Applications
  • 6. 4. Global Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pharmaceutical
  • Biotechnology
  • Food and Beverage
  • Other End Users

7. Enzyme Inhibitor Market Regional And Country Analysis

  • 7.1. Global Enzyme Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Enzyme Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Enzyme Inhibitor Market

  • 8.1. Asia-Pacific Enzyme Inhibitor Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8. 4. Asia-Pacific Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Enzyme Inhibitor Market

  • 9.1. China Enzyme Inhibitor Market Overview
  • 9.2. China Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9. 4. China Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Enzyme Inhibitor Market

  • 10.1. India Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Enzyme Inhibitor Market

  • 11.1. Japan Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Enzyme Inhibitor Market

  • 12.1. Australia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Enzyme Inhibitor Market

  • 13.1. Indonesia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Enzyme Inhibitor Market

  • 14.1. South Korea Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Enzyme Inhibitor Market

  • 15.1. Western Europe Enzyme Inhibitor Market Overview
  • 15.2. Western Europe Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15. 4. Western Europe Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Enzyme Inhibitor Market

  • 16.1. UK Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Enzyme Inhibitor Market

  • 17.1. Germany Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Enzyme Inhibitor Market

  • 18. 5. France Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 6. France Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 7. France Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Enzyme Inhibitor Market

  • 19. 9. Italy Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Enzyme Inhibitor Market

  • 20.13. Spain Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Enzyme Inhibitor Market

  • 21.1. Eastern Europe Enzyme Inhibitor Market Overview
  • 21.2. Eastern Europe Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21. 4. Eastern Europe Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Enzyme Inhibitor Market

  • 22.1. Russia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Enzyme Inhibitor Market

  • 23.1. North America Enzyme Inhibitor Market Overview
  • 23.2. North America Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23. 4. North America Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Enzyme Inhibitor Market

  • 24.1. USA Enzyme Inhibitor Market Overview
  • 24.2. USA Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24. 4. USA Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Enzyme Inhibitor Market

  • 25.1. Canada Enzyme Inhibitor Market Overview
  • 25.2. Canada Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25. 4. Canada Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Enzyme Inhibitor Market

  • 26.1. South America Enzyme Inhibitor Market Overview
  • 26.2. South America Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26. 4. South America Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Enzyme Inhibitor Market

  • 27.1. Brazil Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Enzyme Inhibitor Market

  • 28.1. Middle East Enzyme Inhibitor Market Overview
  • 28.2. Middle East Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28. 4. Middle East Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Enzyme Inhibitor Market

  • 29.1. Africa Enzyme Inhibitor Market Overview
  • 29.2. Africa Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29. 4. Africa Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Enzyme Inhibitor Market Competitive Landscape And Company Profiles

  • 30.1. Enzyme Inhibitor Market Competitive Landscape
  • 30.2. Enzyme Inhibitor Market Company Profiles
    • 30.2.1. Abbott Laboratories
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. Amgen Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. AstraZeneca plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. Bayer AG
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. F. Hoffmann-La Roche AG
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Enzyme Inhibitor Market Competitive Benchmarking

32. Global Enzyme Inhibitor Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Enzyme Inhibitor Market

34. Enzyme Inhibitor Market Future Outlook and Potential Analysis

  • 34.1 Enzyme Inhibitor Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Enzyme Inhibitor Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Enzyme Inhibitor Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer